Key Market Indicators
New Zealand's antihypertensive medicine sales are on track to remain at $2.2 million by 2026, according to recent forecasts. Since 1998, demand for these medicines has increased by an average of 4% each year. In 2021, New Zealand was ranked 22nd in the world for antihypertensive medicine sales, with Portugal at the top of the list with $2.2 million. Italy, Spain and Australia followed in second, third and fourth place respectively.
New Zealand Antihypertensive Market Data and Forecasts
How much will New Zealand Antihypertensive Market grow to 2026?More in Antihypertensive Industry for 2027
Improve your Knowledge with the latest Indicators and Trends
The anticoagulants market is witnessing a surge in its growth trajectory, primarily driven by demographic changes such as an aging population, which is increasing the demand for these drugs. The rise in prevalence of cardiovascular diseases and lifestyle-related ailments leading to blood clot formation fuels the need for anticoagulants, further...Read more
The field of drugs treating elevated lipid levels, traditionally occupied by statins, has seen considerable progress. New classes, such as PCSK9 inhibitors and mRNA-based therapies, are currently being developed and commercialized. These innovative treatments promise to augment the therapeutic landscape and enhance patient outcomes, especially for those resistant or intolerant...Read more
The anti-hypertensive drugs market is marked by several notable trends, fuelled by globally escalating hypertension prevalence. As per recent forecasts, the sector is anticipated to exhibit steady growth, spurred by a rising pool of geriatric population at risk of high blood pressure. Increasing health awareness and advancements in drug discovery...Read more